News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opexa Therapeutics (OPXA) Immune Monitoring Program Featured in Neurology Reviews



10/21/2013 9:32:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company has been featured in Neurology Reviews. The article, titled "Regulation May Be Impaired in Patients With Secondary Progressive MS,” was written by Erik Greb, the publication's senior associate editor, and presents data from Opexa’s Immune Monitoring program that is part of its ongoing Phase IIb Abili-T trial in Secondary Progressive MS (SPMS).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES